MET-directed therapies, including tyrosine kinase inhibitors (TKIs) and monoclonal antibodies targeting MET, MET ligands, or the hepatocyte growth factor (HGF) [5,6,7], have been tested in patients with advanced NSCLC with MET deregulation, mainly due to exon 14 skipping mutations (METex14) or MET amplification (MET-amp). The gene discussed is HGF; the disease is non-small cell lung carcinoma.